The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal ...

A list of suggestions for customizing IGF-IR targeting is provided in the Executive summary. One has to seriously consider the hypothesis that cancer cells can acquire the ability of using one ...

智通财经APP获悉，天风证券发布研究报告称，维持信达生物(01801)“买入”评级，考虑到公司已上市产品持续放量，多条研发管线即将进入产品收获期，将2024和2025年的收入预期分别从72.25、91.93亿元上调至79.70、102.35亿元，预计 ...

With potential to have lonigutamab as a possible best-in-class anti-IGF-1R drug for TED, plus moving rapidly into phase 3 clinical testing, I believe that investors could benefit with any ...

Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful ...

Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody. The THRIVE-2 study (NCT06021054) of veligrotug in patients with chronic TED is fully enrolled ...

The insulin-like growth factor 1 (IGF1) signaling pathway is implicated in the development of cancer. High levels of circulating IGF1 and certain genetic polymorphisms of IGF1 and IGFBP3 are ...

Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics ...

Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody. The THRIVE-2 study (NCT06021054) of veligrotug in patients with chronic TED is fully enrolled ...